Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society

Jai Min Ryu, Jonghan Yu, Seung Il Kim, Ku Sang Kim, Hyeong Gon Moon, Jung Eun Choi, Jeong Joon, Kyung Do Byun, Seok Jin Nam, Jeong Eon Lee, Se Kyung Lee, Seok Won Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Numerous studies have demonstrated that breast cancer in young women (BCY) has unfavorable prognostic features and more unfavorable subtypes. However, few studies have evaluated the effect of subtype disparities on breast cancer prognosis by age, especially for BCY. We analyzed breast cancer mortality stratified by tumor subtype according to age among patients younger than 50 years. Methods: Data from the Korean Breast Cancer Society Registry for patients diagnosed with invasive breast cancer when aged less than 50 years between 2003 and 2010 were reviewed retrospectively. Results: We identified 30,793 patients with breast cancer who were eligible for analysis. Of these, 793 (2.6%) were aged 20–29 and 8926 (28.8%) were aged 30–39. Median follow-up duration was 84 months. Mean age was 42.4 years. Patients in their 20s were more likely to have cancer of advanced stage and higher nuclear grade, present with lymphovascular invasion, and have unfavorable subtypes. Patients in the 20s group showed worse prognosis. In multivariate analysis for overall survival (OS), the hazard ratio (HR) for patients in the 20s group was higher than that for the 30s and 40s groups, and patients with triple-negative breast cancer (TNBC) showed higher HR than patients with HER-2 or luminal subtype (all p < 0.0001). When stratified by subtype, luminal subtype showed significantly worse prognosis in the 20s group than the 30s and 40s groups, whereas HER-2 and TNBC subtypes showed no significant difference. Conclusion: Patients in their 20s with breast cancer had unfavorable characteristics and worse prognosis than patients in their 30s and 40s. When stratified by tumor subtype, patients in their 20s with luminal subtype of breast cancer showed worse prognosis than older patients, whereas HER-2 and TNBC subtypes showed no significant differences.

Original languageEnglish
Pages (from-to)833-842
Number of pages10
JournalBreast Cancer Research and Treatment
Volume166
Issue number3
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms
Registries
Multivariate Analysis
Survival
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ryu, Jai Min ; Yu, Jonghan ; Kim, Seung Il ; Kim, Ku Sang ; Moon, Hyeong Gon ; Choi, Jung Eun ; Joon, Jeong ; Do Byun, Kyung ; Nam, Seok Jin ; Lee, Jeong Eon ; Lee, Se Kyung ; Kim, Seok Won. / Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype : a nationwide study from the Korean Breast Cancer Society. In: Breast Cancer Research and Treatment. 2017 ; Vol. 166, No. 3. pp. 833-842.
@article{6f8639689f65416cb1ea963d02c98889,
title = "Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society",
abstract = "Purpose: Numerous studies have demonstrated that breast cancer in young women (BCY) has unfavorable prognostic features and more unfavorable subtypes. However, few studies have evaluated the effect of subtype disparities on breast cancer prognosis by age, especially for BCY. We analyzed breast cancer mortality stratified by tumor subtype according to age among patients younger than 50 years. Methods: Data from the Korean Breast Cancer Society Registry for patients diagnosed with invasive breast cancer when aged less than 50 years between 2003 and 2010 were reviewed retrospectively. Results: We identified 30,793 patients with breast cancer who were eligible for analysis. Of these, 793 (2.6{\%}) were aged 20–29 and 8926 (28.8{\%}) were aged 30–39. Median follow-up duration was 84 months. Mean age was 42.4 years. Patients in their 20s were more likely to have cancer of advanced stage and higher nuclear grade, present with lymphovascular invasion, and have unfavorable subtypes. Patients in the 20s group showed worse prognosis. In multivariate analysis for overall survival (OS), the hazard ratio (HR) for patients in the 20s group was higher than that for the 30s and 40s groups, and patients with triple-negative breast cancer (TNBC) showed higher HR than patients with HER-2 or luminal subtype (all p < 0.0001). When stratified by subtype, luminal subtype showed significantly worse prognosis in the 20s group than the 30s and 40s groups, whereas HER-2 and TNBC subtypes showed no significant difference. Conclusion: Patients in their 20s with breast cancer had unfavorable characteristics and worse prognosis than patients in their 30s and 40s. When stratified by tumor subtype, patients in their 20s with luminal subtype of breast cancer showed worse prognosis than older patients, whereas HER-2 and TNBC subtypes showed no significant differences.",
author = "Ryu, {Jai Min} and Jonghan Yu and Kim, {Seung Il} and Kim, {Ku Sang} and Moon, {Hyeong Gon} and Choi, {Jung Eun} and Jeong Joon and {Do Byun}, Kyung and Nam, {Seok Jin} and Lee, {Jeong Eon} and Lee, {Se Kyung} and Kim, {Seok Won}",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s10549-017-4472-5",
language = "English",
volume = "166",
pages = "833--842",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype : a nationwide study from the Korean Breast Cancer Society. / Ryu, Jai Min; Yu, Jonghan; Kim, Seung Il; Kim, Ku Sang; Moon, Hyeong Gon; Choi, Jung Eun; Joon, Jeong; Do Byun, Kyung; Nam, Seok Jin; Lee, Jeong Eon; Lee, Se Kyung; Kim, Seok Won.

In: Breast Cancer Research and Treatment, Vol. 166, No. 3, 01.12.2017, p. 833-842.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype

T2 - a nationwide study from the Korean Breast Cancer Society

AU - Ryu, Jai Min

AU - Yu, Jonghan

AU - Kim, Seung Il

AU - Kim, Ku Sang

AU - Moon, Hyeong Gon

AU - Choi, Jung Eun

AU - Joon, Jeong

AU - Do Byun, Kyung

AU - Nam, Seok Jin

AU - Lee, Jeong Eon

AU - Lee, Se Kyung

AU - Kim, Seok Won

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Purpose: Numerous studies have demonstrated that breast cancer in young women (BCY) has unfavorable prognostic features and more unfavorable subtypes. However, few studies have evaluated the effect of subtype disparities on breast cancer prognosis by age, especially for BCY. We analyzed breast cancer mortality stratified by tumor subtype according to age among patients younger than 50 years. Methods: Data from the Korean Breast Cancer Society Registry for patients diagnosed with invasive breast cancer when aged less than 50 years between 2003 and 2010 were reviewed retrospectively. Results: We identified 30,793 patients with breast cancer who were eligible for analysis. Of these, 793 (2.6%) were aged 20–29 and 8926 (28.8%) were aged 30–39. Median follow-up duration was 84 months. Mean age was 42.4 years. Patients in their 20s were more likely to have cancer of advanced stage and higher nuclear grade, present with lymphovascular invasion, and have unfavorable subtypes. Patients in the 20s group showed worse prognosis. In multivariate analysis for overall survival (OS), the hazard ratio (HR) for patients in the 20s group was higher than that for the 30s and 40s groups, and patients with triple-negative breast cancer (TNBC) showed higher HR than patients with HER-2 or luminal subtype (all p < 0.0001). When stratified by subtype, luminal subtype showed significantly worse prognosis in the 20s group than the 30s and 40s groups, whereas HER-2 and TNBC subtypes showed no significant difference. Conclusion: Patients in their 20s with breast cancer had unfavorable characteristics and worse prognosis than patients in their 30s and 40s. When stratified by tumor subtype, patients in their 20s with luminal subtype of breast cancer showed worse prognosis than older patients, whereas HER-2 and TNBC subtypes showed no significant differences.

AB - Purpose: Numerous studies have demonstrated that breast cancer in young women (BCY) has unfavorable prognostic features and more unfavorable subtypes. However, few studies have evaluated the effect of subtype disparities on breast cancer prognosis by age, especially for BCY. We analyzed breast cancer mortality stratified by tumor subtype according to age among patients younger than 50 years. Methods: Data from the Korean Breast Cancer Society Registry for patients diagnosed with invasive breast cancer when aged less than 50 years between 2003 and 2010 were reviewed retrospectively. Results: We identified 30,793 patients with breast cancer who were eligible for analysis. Of these, 793 (2.6%) were aged 20–29 and 8926 (28.8%) were aged 30–39. Median follow-up duration was 84 months. Mean age was 42.4 years. Patients in their 20s were more likely to have cancer of advanced stage and higher nuclear grade, present with lymphovascular invasion, and have unfavorable subtypes. Patients in the 20s group showed worse prognosis. In multivariate analysis for overall survival (OS), the hazard ratio (HR) for patients in the 20s group was higher than that for the 30s and 40s groups, and patients with triple-negative breast cancer (TNBC) showed higher HR than patients with HER-2 or luminal subtype (all p < 0.0001). When stratified by subtype, luminal subtype showed significantly worse prognosis in the 20s group than the 30s and 40s groups, whereas HER-2 and TNBC subtypes showed no significant difference. Conclusion: Patients in their 20s with breast cancer had unfavorable characteristics and worse prognosis than patients in their 30s and 40s. When stratified by tumor subtype, patients in their 20s with luminal subtype of breast cancer showed worse prognosis than older patients, whereas HER-2 and TNBC subtypes showed no significant differences.

UR - http://www.scopus.com/inward/record.url?scp=85027849650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027849650&partnerID=8YFLogxK

U2 - 10.1007/s10549-017-4472-5

DO - 10.1007/s10549-017-4472-5

M3 - Article

C2 - 28831642

AN - SCOPUS:85027849650

VL - 166

SP - 833

EP - 842

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -